[Taipei, Taiwan – September 30, 2026]
Mycenax Biotech Inc. (4726) received the Silver Award in the International Advancement category at the 2026 Taipei Biotech Awards, recognizing the company’s progress in international expansion, cross-border collaboration, and commercial biologics manufacturing.
This year, 35 judges reviewed 151 applications, with 20 companies selected for recognition, representing an overall award rate of approximately 13%.
In recent years, Mycenax has continued to deepen its presence in Japan. In 2025, the company joined Alfresa, Kidswell Bio, and Chiome Bioscience to establish Alfenax Biologics Corporation, advancing plans for a biologics manufacturing facility in Japan and building a dual-site manufacturing network across Taiwan and Japan.
Beyond Taiwan-Japan collaboration, Mycenax continues to work with global technology partners to expand its biologics and ADC development and manufacturing capabilities. Its commercial manufacturing experience and international regulatory track record further support the company’s growing role in the global biopharmaceutical supply chain.
Pei-Jiun Chen, CEO & President of Mycenax, commented, “This award recognizes the progress Mycenax has made in international expansion and cross-border collaboration. We will continue to deepen our presence in Japan and strengthen partnerships with global industry and technology partners.”
Looking ahead, Mycenax will continue to leverage Taiwan as its core development and manufacturing base while expanding its presence in Japan and other international markets.
Caption: Mycenax receives the Silver Award for International Advancement at the 2026 Taipei Biotech Awards, recognizing its progress in global expansion and cross-border collaboration.
Photo courtesy of Mycenax Biotech Inc.
About Mycenax
Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) and well-scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).
Mycenax was established in September 2001, and current capital is NT$2.07 billion.
Stock Code: Mycenax (4726)
Official Website: http://www.mycenax.com
Press Contact:
Liru Yeh
Tel: +886-2-2655-8951 Ext. 6102
Email: liru.yeh@mycenax.com
[Taipei, Taiwan – September 30, 2026]
Mycenax Biotech Inc. (4726) received the Silver Award in the International Advancement category at the 2026 Taipei Biotech Awards, recognizing the company’s progress in international expansion, cross-border collaboration, and commercial biologics manufacturing.
This year, 35 judges reviewed 151 applications, with 20 companies selected for recognition, representing an overall award rate of approximately 13%.
In recent years, Mycenax has continued to deepen its presence in Japan. In 2025, the company joined Alfresa, Kidswell Bio, and Chiome Bioscience to establish Alfenax Biologics Corporation, advancing plans for a biologics manufacturing facility in Japan and building a dual-site manufacturing network across Taiwan and Japan.
Beyond Taiwan-Japan collaboration, Mycenax continues to work with global technology partners to expand its biologics and ADC development and manufacturing capabilities. Its commercial manufacturing experience and international regulatory track record further support the company’s growing role in the global biopharmaceutical supply chain.
Pei-Jiun Chen, CEO & President of Mycenax, commented, “This award recognizes the progress Mycenax has made in international expansion and cross-border collaboration. We will continue to deepen our presence in Japan and strengthen partnerships with global industry and technology partners.”
Looking ahead, Mycenax will continue to leverage Taiwan as its core development and manufacturing base while expanding its presence in Japan and other international markets.
Caption: Mycenax receives the Silver Award for International Advancement at the 2026 Taipei Biotech Awards, recognizing its progress in global expansion and cross-border collaboration.
Photo courtesy of Mycenax Biotech Inc.
About Mycenax
Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) and well-scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).
Mycenax was established in September 2001, and current capital is NT$2.07 billion.
Stock Code: Mycenax (4726)
Official Website: http://www.mycenax.com
Press Contact:
Liru Yeh
Tel: +886-2-2655-8951 Ext. 6102
Email: liru.yeh@mycenax.com
